Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optional Prospective Follow-on Study to Evaluate Continued Efficacy and Safety of Cat-PAD up to Five Years
2013-004669-15Phase 3Completed
- Sponsor
- NIOX Group
- Start
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Cat-PAD in allergic rhinitis (AR), allergic conjunctivitis (AC) and cat allergy, sponsored by NIOX Group. Primary endpoint: Mean Combined Score. Started Apr 2014; status: completed.
02
Drugs
Cat-PAD
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)cat allergy
Beyond the preview
Go deeper on 2013-004669-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004669-15.